Abstract
Erythropoietin (EPO) acts on erythroblasts in the bone marrow (BM) to stimulate the formation of red blood cells. In this study, we wanted to determine whether BM-derived mesenchymal stromal cells (MSCs) can be used as cellular vehicles to deliver EPO in mice without the use of viral vectors. After isolation and characterization of murine MSCs (mMSCs), different transient transfection procedures were compared for their efficacy of gene transfer of the pEGFP-N2 plasmid. Nucleofection outperformed magnetofection and lipofection. Stably transfected mMSCs were generated by selection with G418-disulfate and single-cell-colony-forming unit (sc-CFU) assays without changes in their proliferation capacity and osteogenic/adipogenic differentiation potential. Next, murine EPO was stably introduced into mMSCs by nucleofection of a plasmid encoding the epo and egfp genes. Intraperitoneal transplantation of EPO-expressing mMSCs increased serum EPO levels, hematocrit and hemoglobin of C57BL/6 mice within 1 week. The hematocrit remained elevated for 5 weeks, but production of antibodies against both transgenes was detected in the hosts and serum EPO levels normalized. Our results suggest that nonviral gene delivery into MSCs can be used to enhance the known beneficial effects MSCs by additional production of therapeutic factors like EPO in vivo.
Similar content being viewed by others
References
Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580–7584.
Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002; 22: 10291–10301.
Arcasoy MO . The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14–31.
Osada S, Ebihara I, Setoguchi Y, Takahashi H, Tomino Y, Koide H . Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene. Kidney Int 1999; 55: 1234–1240.
Oh TK, Quan GH, Kim HY, Park F, Kim ST . Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene. Am J Nephrol 2006; 26: 326–334.
Daga A, Muraglia A, Quarto R, Cancedda R, Corte G . Enhanced engraftment of EPO-transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned NOD/SCID mice. Gene Therapy 2002; 9: 915–921.
Voutetakis A, Zheng C, Cotrim AP, Mineshiba F, Afione S, Roescher N et al. AAV5-mediated gene transfer to the parotid glands of non-human primates. Gene Therapy 2010; 17: 50–60.
Svensson EC, Black HB, Dugger DL, Tripathy SK, Goldwasser E, Hao Z et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum Gene Ther 1997; 8: 1797–1806.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147.
Pereira RF, Halford KW, O’Hara MD, Leeper DB, Sokolov BP, Pollard MD et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 1995; 92: 4857–4861.
Sanz L, Compte M, Guijarro-Muñoz I, Álvarez-Vallina L . Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Therapy 2011; e-pub ahead of print 12 May 2011; doi:10.1038/gt.2011.68.
Caplan AI . Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217: 318–324.
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838–3843.
Bartholomew A, Patil S, Mackay A, Nelson M, Buyaner D, Hardy W et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001; 12: 1527–1541.
Yokoo T, Fukui A, Matsumoto K, Ohashi T, Sado Y, Suzuki H et al. Generation of a transplantable erythropoietin-producer derived from human mesenchymal stem cells. Transplantation 2008; 85: 1654–1658.
Eliopoulos N, Al Khaldi A, Crosato M, Lachapelle K, Galipeau J . A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Therapy 2003; 10: 478–489.
Copland IB, Jolicoeur EM, Gillis MA, Cuerquis J, Eliopoulos N, Annabi B et al. Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res 2008; 79: 405–415.
Eliopoulos N, Gagnon RF, Francois M, Galipeau J . Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol 2006; 17: 1576–1584.
Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Ishii K, Kobune M et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther 2005; 11: 96–104.
Eliopoulos N, Lejeune L, Martineau D, Galipeau J . Human-compatible collagen matrix for prolonged and reversible systemic delivery of erythropoietin in mice from gene-modified marrow stromal cells. Mol Ther 2004; 10: 741–748.
Campeau PM, Rafei M, Francois M, Birman E, Forner KA, Galipeau J . Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther 2009; 17: 369–372.
Phillips JE, Gersbach CA, Garcia AJ . Virus-based gene therapy strategies for bone regeneration. Biomaterials 2007; 28: 211–229.
Gothelf A, Hojman P, Gehl J . Therapeutic levels of erythropoietin (EPO) achieved after gene electrotransfer to skin in mice. Gene Therapy 2010; 17: 1077–1084.
Gothelf A, Eriksen J, Hojman P, Gehl J . Duration and level of transgene expression after gene electrotransfer to skin in mice. Gene Therapy 2010; 17: 839–845.
Eguchi H, Kuroiwa Y, Matsui A, Sada M, Nagaya N, Kawano S . Intra-bone marrow cotransplantation of donor mesenchymal stem cells in pig-to-NOD/SCID mouse bone marrow transplantation facilitates short-term xenogeneic hematopoietic engraftment. Transplant Proc 2008; 40: 574–577.
Coyne TM, Marcus AJ, Reynolds K, Black IB, Woodbury D . Disparate host response and donor survival after the transplantation of mesenchymal or neuroectodermal cells to the intact rodent brain. Transplantation 2007; 84: 1507–1516.
Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54–63.
Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction. Circ J 2010; 74: 1415–1423.
Price MJ, Chou CC, Frantzen M, Miyamoto T, Kar S, Lee S et al. Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol 2006; 111: 231–239.
Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110: 1362–1369.
Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J . Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005; 106: 4057–4065.
Sauerborn M, Brinks V, Jiskoot W, Schellekens H . Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010; 31: 53–59.
Schellekens H . Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20 (Suppl 6): vi3–vi9.
McMahon JM, Conroy S, Lyons M, Greiser U, O'shea C, Strappe P et al. Gene transfer into rat mesenchymal stem cells: a comparative study of viral and nonviral vectors. Stem Cells Dev 2006; 15: 87–96.
Colleoni S, Donofrio G, Lagutina I, Duchi R, Galli C, Lazzari G . Establishment, differentiation, electroporation, viral transduction, and nuclear transfer of bovine and porcine mesenchymal stem cells. Cloning Stem Cells 2005; 7: 154–166.
Aslan H, Zilberman Y, Arbeli V, Sheyn D, Matan Y, Liebergall M et al. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng 2006; 12: 877–889.
Ferreira E, Potier E, Logeart-Avramoglou D, Salomskaite-Davalgiene S, Mir LM, Petite H . Optimization of a gene electrotransfer method for mesenchymal stem cell transfection. Gene Therapy 2008; 15: 537–544.
Aluigi M, Fogli M, Curti A, Isidori A, Gruppioni E, Chiodoni C et al. Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 454–461.
Nakashima S, Matsuyama Y, Nitta A, Sakai Y, Ishiguro N . Highly efficient transfection of human marrow stromal cells by nucleofection. Transplant Proc 2005; 37: 2290–2292.
Zaragosi LE, Billon N, Ailhaud G, Dani C . Nucleofection is a valuable transfection method for transient and stable transgene expression in adipose tissue-derived stem cells. Stem Cells 2007; 25: 790–797.
Gheisari Y, Soleimani M, Azadmanesh K, Zeinali S . Multipotent mesenchymal stromal cells: optimization and comparison of five cationic polymer-based gene delivery methods. Cytotherapy 2008; 10: 815–823.
Laker C, Meyer J, Schopen A, Friel J, Heberlein C, Ostertag W et al. Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation. J Virol 1998; 72: 339–348.
Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ . Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004; 103: 1662–1668.
Sekiya I, Larson BL, Vuoristo JT, Reger RL, Prockop DJ . Comparison of effect of BMP-2, -4, and -6 on in vitro cartilage formation of human adult stem cells from bone marrow stroma. Cell Tissue Res 2005; 320: 269–276.
Acknowledgements
We thank Sonja Blumenau, Anna Hegele, Jasmin Jamal el-Din, Melanie Lange and Katharina Stohlmann for their excellent technical assistance. We also thank Benjamin Larson and Dina Gaupp for their support with cartilage differentiation. This study was supported by grants from the BMBF, Research Grant No. 01GN0508, the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the DFG Excellence Cluster NeuroCure.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Scheibe, F., Gladow, N., Mergenthaler, P. et al. Nonviral gene delivery of erythropoietin by mesenchymal stromal cells. Gene Ther 19, 550–560 (2012). https://doi.org/10.1038/gt.2011.139
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2011.139
- Springer Nature Limited
Keywords
This article is cited by
-
Gene Transfection for Stem Cell Therapy
Current Stem Cell Reports (2016)